Study of Healthy Aging and Physical Function With Elamipretide

Summary

This study will utilize a daily dose of elamipetide for 4 weeks and will screen a sufficient number of subjects for 30 subjects to enroll in the study. The planned duration of the study includes baseline measurement, followed by 4 weeks intervention period, a midpoint (2week ±3days) check-in phone interview, and post intervention visits that mirror the baseline visits. After the last injection, subjects will enter the 2-week follow-up period, concluded by the end-of-study contact.

Timeline

Start

2025-11-26

Primary completion

2026-03-15

Completion

2026-04-15

Drugs

Indications

No indication recorded.